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Abstract
Background: In-depth phylogeographic analysis can reveal migration patterns relevant for public health planning.
Here, as a model, we focused on the provenance, in the current Italian HCV subtype 1a epidemic, of the NS3
resistance-associated variant (RAV) Q80K, known to interfere with the action of NS3/4A protease inhibitor simeprevir.
HCV1a migration patterns were analysed using Bayesian phylodynamic tools, capitalising on newly generated and
publicly available time and geo-referenced NS3 encoding virus genetic sequence data.
Results: Our results showed that both immigration and local circulation fuel the current Italian HCV1a epidemic. The
United States and European continental lineages dominate import into Italy, with the latter taking the lead from the
1970s onwards. Since similar migration patterns were found for Q80K and other lineages, no clear differentiation of the
risk for failing simeprevir can be made between patients based on their migration and travel history. Importantly, since
HCV only occasionally recombines, these results are readily transferable to the genetic sequencing policy concerning
NS5A RAVs.
Conclusions: The patient migration and travel history cannot be used to target only part of the HCV1a infected
population for drug resistance testing before start of antiviral therapy. Consequently, it may be cost-effective to
expand genotyping efforts to all HCV1a infected patients eligible for simeprevir-based therapies.
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Background
Hepatitis C virus (HCV) infected patients are nowadays
treated with interferon-free regimens containing one or
more antivirals that directly target virus proteins. These
new direct-acting antivirals (DAAs) have a superb effi-
cacy and, when combined, can clear the virus in more
than 95% of the treated population, irrespective of the
HCV genotype [1]. For most DAAs no clear association
of particular naturally occurring resistance-associated vari-
ants (RAVs) with clinical outcome has been identified [2].
Because of this, baseline drug resistance testing is only
recommended in well-defined cases such as the com-
bination of NS3/4A protease inhibitor (PI) simeprevir
with NS5B polymerase inhibitor sofosbuvir. This regi-
men is associated with reduced viral cure rates in HCV
subtype 1a (HCV1a) cirrhotic patients who carry the nat-
urally occurring, highly prevalent RAV Q80K [3–6]. The
potential clinical relevance of the processes that shape the
distribution of particular variants spurred an interest in
the spatiotemporal aspects of the HCV1a evolutionary
history in general, and in particular that of NS3 variant
Q80K. Given the increased interest into the natural preva-
lence of several other RAVs, particularly located in NS5A
[4, 7], insights into the patterns of HCV1a spread may be
interesting for these variants as well.
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Little over a decade after the discovery of the virus it-
self, it was revealed that there was a burst in the number
of HCV1a transmissions starting from the second half of
the 20th century, which is likely linked to the history of
illicit drug use and iatrogenic intervention rates [8–11].
While in these earlier studies the emphasis was on the
temporal and spatial aspects of HCV1a in general, the
medical relevance of the Q80K polymorphism drew atten-
tion to the segregation of the global HCV1a variability
into two distinct clades, clade I and clade II [12–15], with
the first clade further structured into three subclades [16].
In particular, Q80K strains are concentrated in the so-
called clade IA [16], and the Q80K prevalence is largely
accounted for by a single substitution event dating back to
1940–1963 [17]. This ancestral lineage first arose in the
United States (US) and has been introduced multiple
times into Europe [13, 14, 17]. Importantly, in these
studies the migration patterns of HCV1a were evaluated
on the continental geographical level, while a more fine-
grained resolution is required to provide actionable infor-
mation for national or regional public health programs.
Detailed phylogeographic analyses are particularly per-
tinent for clinically relevant lineages. Due to the rapid
evolution of HCV treatments that achieve high viral cure
rates, the regimen simeprevir with sofosbuvir, largely
used as first-line treatment so far in Europe and in Italy
[18, 19], has recently been categorized as suboptimal for
HCV1a infected patients [20]. Nonetheless, second-line
NS5A inhibitor-based regimens can still be considered
when the absence of relevant RAVs is confirmed [21].
Despite this shift from NS3-targeting DAAs to those
that inhibit the NS5A protein, a thorough analysis of the
patterns of virus flow based on the NS3 region remains
valuable because HCV only rarely recombines [22], and
migration patterns inferred from small genomic regions
hence have a genome-wide representativeness. More-
over, because drug resistance testing before treatment
initiation has always been recommended for HCV1a in-
fected patients when simeprevir is part of the planned
regimen, NS3-based phylogeographic reconstructions
can capitalize on a comparatively large number of pub-
licly available NS3 sequence data to obtain the most ac-
curate insights as possible. However, the rapid evolution
in preferred HCV treatment schemes makes that phylo-
geographically informed public health decisions are of
temporal value, and need to be updated regularly.
Here, we reconstructed the historical spread of HCV1a
using a within-country-level resolution, and focused on
the potential public health implications of the recovered
clustering patterns for Italy. To this end, new sequencing
data of the NS3 gene from Italy were combined with a se-
lection of globally sampled publicly available sequences to
infer the plausible origins and frequencies of HCV1a mi-
grations into and out of Italy, and to explore the within-
country migration flows for Italy, with statistical phylogeo-
graphic tools. In doing so, we provide a blueprint of how
similar studies with a focus on other genomic regions in
the HCV genome like the NS5A protein, or even other
viruses can analyze patterns of virus flow by integrating
genetic, spatial and temporal information in a state-of-
the-art Bayesian phylogenetic framework. Furthermore,
the timing of the Q80K origins was refined and the histor-
ical context of their spread from the US to Europe and
Italy was discussed.
Methods
Newly generated Italian sequences
This retrospective study includes 183 samples, collected
between 2011–2015, from mostly DAA-naïve (N = 163,
89.1%) Italian patients infected with HCV1a. The Italian
strains were collected in at least seven regions (Additional
file 1: Table S1). The NS3 protease gene (181 amino acids)
was sequenced as reported elsewhere [23] in the context
of routine clinical care at University of Rome Tor Vergata,
Italy (art. 6 and art. 9, leg. 211/2003 and 196/2003).
Sequence dataset compilation
The Italian sequence data were complemented with all
publicly available HCV1a NS3 sequences from Genbank
(N = 3032, http://www.ncbi.nlm.nih.gov/nucleotide) that
fulfilled the following quality criteria. Only sequences
that were unambiguously subtyped as HCV1a with sub-
typing tools Oxford HCV version 2 [24], COMET [25],
and by phylogenetic analysis including a broad panel of
reference sequences, were retained. The latter phyloge-
nies were estimated on 1000 bootstrapped alignments
with RAxML under a GTR + Γ substitution model, with
subtypes assigned to strains clustering with ≥70% boot-
strap support. Clonal sequences and strains from non-
human hosts, duplicate sequences and strains covering
<80% of the NS3 gene were removed. Remaining strains
were aligned using an in house pairwise codon aware
alignment tool (http://regatools.med.kuleuven.be/sequen-
cetool/sequencetool.wt), followed by the removal of se-
quences with stop codons, leaving 930 taxa. Of these, 855
sequences with known sampling time and location were
used for the phylogeographic reconstructions. A prelimin-
ary analysis revealed a large clade with only US-derived
sequences that did not contain NS3 RAVs and that
received 100% bootstrap support. As the within-US circu-
lation was not the focus of this study, sequences from this
clade were discarded to reduce computational burden in
subsequent Bayesian analyses, resulting in a final set of
610 strains (Table 1).
To assess the robustness of the phylogeographic recon-
structions against sampling biases, three random down-
samples with a maximum of 30 sequences per location
were created, resulting in three sets with a more balanced
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number of samples by location. Additionally, a diverse
subset of 83 sequences was selected from clade I using the
same procedure as in [26] to independently estimate the
evolutionary rate in the Q80K clade. Briefly, from each
sampling year the five most divergent sequences were se-
lected with the Phylogenetic Diversity Algorithm [27],
which selects the subtree of n taxa connected by the lar-
gest sum of branch lengths.
Identification of Italian transmission networks
Transmission clusters that represent the Italian trans-
mission dynamics were identified using a posterior root
node support cutoff of ≥90% and were required to con-
sist at least for 90% of member taxa isolated in Italy.
Bayesian estimation of time-calibrated trees
All phylogenies were estimated using the Bayesian
Evolutionary Analysis by Sampling Trees software
(BEAST, v.1.8.2.) [28] with BEAGLE [29] to improve
the computational performance. The skygrid or skyride
model was used as a flexible non-parametric prior for
the coalescent process in all analyses. A check for molecu-
lar clock signal [30] revealed that there was insufficient
accumulation of divergence over the sampling time span
to reliably estimate evolutionary rates. A first attempt to
remedy this was specifying an informative prior distribu-
tion on the mean clock rate parameter of the relaxed clock
model [31] that is based on a previously reported HCV1a
dataset with strong temporal signal [32]. Exploratory runs
with this model setup, however, indicated this still repre-
sented an overparameterization, which is why the mean
clock rate was fixed to the mean of the NS3 rate estimate
from the Gray et al. (2011) data, but while still estimating
the variance of the evolutionary rate. A codon position
partitioned HKY model was fitted, allowing for Γ-
distributed among site rate heterogeneity at each position.
Convergence and mixing properties of the Markov chain
Monte Carlo (MCMC) chains were assessed with Tracer
v1.6. Results of several MCMC chains were combined
after removal of the burn-in. Maximum clade credibility
(MCC) trees were summarized using TreeAnnotator in-
cluded in the BEAST package. Trees were visualized with
FigTree v 1.4.2 (http://tree.bio.ed.ac.uk/software/figtree/).
Phylogeographic reconstructions
Source-sink relations were evaluated with a discrete dif-
fusion model that allows for different rates depending
on the direction of movement [33]. The migration path-
ways that are most relevant in the history of spread were
identified with a Bayesian stochastic search variable
selection (BSSVS) approach [34]. Bayes factor (BF) sup-
port (with BF ≥3 assumed to be relevant [35]) for all
possible types of location exchanges was calculated using
SpreaD3 [36]. Posterior expectations of the number of
transition events between all possible pairs of locations
(Markov jumps) were estimated with efficient stochastic
mapping techniques [37].
Results
Sequence dataset
The final alignment included 610 sequences and covered
181 amino acids of the NS3 gene. Italy is the best-
represented country in this final dataset, followed by the
US (Table 1). Of the Western European strains, 36.4%
was isolated in countries other than Italy. The Q80K
variant was detected in 23.9% of all strains, and a some-
what lower prevalence of 19.3% was observed for Western
Europe. The proportion of taxa carrying Q80K varied
from 13.0% to 32.0% by country (Table 1).
Multiple independent introductions of HCV1a and Q80K
in Italy
Bayesian phylogeographic methods were used to deter-
mine when and from where HCV1a strains were intro-
duced into Italy. As only limited sequence data was
available for most European countries, all non-Italian
isolates from Europe were grouped as ‘Europe (not
Italy)’. Similarly, isolates sampled outside the US and
Europe were grouped as ‘others’. To mitigate the poten-
tially biasing effect of sample sizes on ancestral recon-
structions of the location states, three subsampled
datasets with more equal sample numbers by location
Table 1 Overview of the complete dataset used in this study
Geographic origin HCV1a dataset
(n, % dataset)
Q80K
(n, % country)
Sample time
span
Italya 280 (45.9) 52 (18.6) 2004-2015
USb 145 (23.8) 58 (24.6)c 1989-2008
Germany 67 (11.0) 19 (28.4) 2003-2013
Switzerland 46 (4.5) 6 (13.0) 2002-2006
Belgium 25 (4.1) 8 (32.0) 2007-2013
Thailand 19 (3.1) 3 (15.8) 2007-2010
France 13 (2.1) / 2007-2011
Spain 5 (0.8) / 2001-2002
UK 4 (0.7) / 2008-2010
Brazil 2 (0.3) / 2001-2003
Australia 2 (0.3) / 2007
China 1 (0.2) / 2009
Japan 1 (0.2) / 2009
Total 610 146 (23.9) 1989-2015
The absolute and relative contribution of each country, the number of Q80K
variants and their share by country, and the time span of the samples
included per country, are detailed. a183 (63%) of the Italian sequences have
not been published before. bTo assess the proportion of Q80K strains, the 91
taxa from the removed cluster were taken into account (see Methods). cSince
the Q80K prevalence in the US was lower than expected, it was recalculated
taking strains without sampling time information into account, resulting into
a prevalence of 57.5%
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state were analyzed (US, Italy, Europe (not Italy) and
others).
Independent of the sampling, similar migration pat-
terns were observed in the two major HCV1a clades as
well as among the clade 1 subclades, including the clade
that comprises virtually all Q80K lineages, to which we
from now on refer to as the Q80K clade (Fig. 1a-d). The
most clear re-emerging pattern in the complete and in
the subsampled datasets is the seeding, but not receiving,
role of the US in the global spread of HCV1a. Specifically,
the migration rates involving the US as origin location
always receive high support for being non-zero, while
rates of migration towards the US are indistinguishable
from zero (Table 2). The remaining three well-supported
migration links in the complete dataset received substan-
tial Bayes factor (BF) support in two out of three subsam-
pled datasets. Two of these links involve Italy, and lend
support for Italy as a source and a sink for European con-
tinental virus movements. An interactive web-based
visualization and demo video of the phylogeographic his-
tory of HCV1a in general and in particular of the Q80K
polymorphism is available at http://demo.luciad.com/
rega/?hepa&2d (legend, see Additional file 2).
In addition to the significance of migration rates, the
expected proportion of all possible migration events in
the HCV1a history (Markov jumps) was also inferred
(Table 2). Little over half of all expected migrations are
virus movements from the US, and a majority of these
are directed towards Western Europe. The virus flows
involving Italy account for 83.4% of the remaining
expected number of jumps, and Italy mostly acts as the
destination location in this European continental spread
(73.9%). Using the entire dataset, the first introduction
of HCV1a into Italy was timed around 1957.7 (95%
HPD: 1949.0-1964.4) (Fig. 1), and the first appearance of
a Q80K lineage in Italy around 1961.5 (95% HPD:
1957.6-1965.7).
The picture painted by the Markov jumps analysis
above is a static one and does not inform us on changes
over time of the relative importance of the migration
flows to and from Italy. A plot of the expected number
of migration events from Italy reveals a stable pattern of
seeding almost uniquely towards other Western European
countries throughout the history (Fig. 2, left panel). In
contrast, a similar plot for the incoming migrations shows
that the initial dominance of the US as origin location has
decreased in favor of European continental HCV1a circu-
lation, starting from 1970 (Fig. 2, right panel).
Migration patterns within Italy
Twelve highly supported small clusters with only Italian
isolates (size range: 2–7) and one pure Italian large clus-
ter (size 34, cluster 13 in Table 3) were identified in the
MCC summary tree of the time evolutionary histories
(Additional file 3: Figure S1). Information on the sam-
pling region (North, Central, South) was available only
for a limited number of the members of the smaller
clusters and for the majority of samples from the large
cluster (Table 3). Both homogenous (n = 1, cluster 4)
and mixed-origin (n = 1, cluster 2) small clusters were
Fig. 1 The United States as the immediate origin of HCV1a spread to Europe and Italy. The branches in the HCV1a maximum clade credibility
(MCC) tree constructed from the complete dataset are colored according to sampling country with strains grouped into four locations (see
legend). All but five Q80K strains are found in the same clade, which is highlighted in grey. We refer to Fig. 3 for further details on the Q80K
history. Mixing of strains among the four locations can be observed in the entire tree. HCV entered Italy via the US and continental migration in
the two major clades of HCV1a variability (Clade I and II) as well as in the Q80K clade. Posterior root node support is visualized in a selection of
deeper nodes. a: entire dataset. b: MCC tree estimated from subsample 1 (see Methods). c: MCC tree estimated from subsample 2. d: MCC tree
estimated from subsample 3
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observed. Phylogeographic analysis of cluster 13 with the
same (asymmetric) model as before painted a picture of
migration by proximity where both North and South
regions interact with the Central region (BF support >3)
and vice versa (BF support >20), but not with each other
(BF support for North-to-South and South-to-North
migration rates <3). There is one larger Italian cluster in
the Q80K clade (Fig. 1), but this has a posterior root
node support of 81%, which is below the used cut-off.
Nonetheless, the distribution of its lineages over at least
five regions (Additional file 4: Table S2) also points to an
interregional mixing of strains within Italy.
Refining Q80K divergence times
As investigating the virus migration patterns entails esti-
mating time-calibrated histories, we seized the oppor-
tunity to briefly re-evaluate the temporal aspects of the
Q80K origins, but now taking among lineage rate vari-
ation explicitly into account. The Q80K variant has
evolved independently on multiple occasions, and one
lineage was particularly successful and gave rise to
almost all currently circulating Q80K strains. This major
Q80K clade had a low posterior support (58.6%), but
upon further inspection it became clear that this was
due to one or a few taxa that frequently clustered
Table 2 Posterior probabilities for all possible types of migrations
Migration from Migration to Complete dataset subsample 1 subsample 2 subsample 3
Europe
(not Italy)
Italy 29.12 2.88 8.48 19.43
US 0.01 0.08 0.09 0.08
Other 7.66 0.81 5.88 11.07
Italy Europe
(not Italy)
10.28 18.23 4.37 0.52
US 0 0.06 0.07 0.05
Other 0.07 8.64 0.47 1.15
US Europe
(not Italy)
21.68 19.08 23.34 21.42
Italy 22.37 22.88 24.37 12.93
Other 8.74 25.61 31.01 29.45
Other
(not Europe –not US)
Europe
(not Italy)
0.03 1.3 0.37 3.61
Italy 0.03 0.33 1.43 0.23
US 0 0.11 0.11 0.08
Posterior probabilities for migration rates supported by a BF ≥3 are marked in bold, indicated for the complete dataset as well as for the three subsamples
created as described in methods
Fig. 2 Immigration and emigration rates of HCV1a strains from and to Italy, over time period 1940–2015. Left panel: Over 99% of exportation
events from Italy are directed towards other European countries (in blue). Note that the rate decline in the most recent years reflects the loss of
branches in the sampling time period, rather than the start of an actual tendency. Right panel: The origin of virtually all strains entering Italy can
be traced back to the United States (US) and other European countries (see Table 2). At the onset of the Italian HCV1a epidemic, immigration was
most intense from the US (in blue). From 1970 onwards, introductions from the European continent started to dominate (in red). The introduction
rate (y-axis) was defined as the median posterior estimate of the expected number of migration events from that particular location per time unit
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outside this dominant Q80K clade (see Fig. 3b-c). The
genesis of the most recent common ancestor of the most
successful Q80K clade was estimated around 1957 (95%
highest posterior density (HPD): 1947.3-1958.6).
In this analysis the mean clock rate was fixed to the
mean of the NS3 rate estimate obtained from the Gray
et al. (2011) HCV1a full-genome data [32]. To verify
whether this did not bias our timing of the origin of the
Q80K clade, a ‘Q80K clade rate’ was estimated inde-
pendently using a subset of this clade’s taxa selected in
the same way as in [26] (see Methods). Reassuringly, the
NS3 mean rate estimates in both analyses were nearly
identical to each other (1.02x10−3 substitutions/site/year
for the Q80K clade, and 1.00x10−3 for the HCV1a NS3
Table 3 Highly supported Italian clusters identified in the MCC tree obtained from the complete dataset
Sample size
(number of strains)
Tree root support
(posterior probability)
Presence of
Q80K (N, %)
Time span
(years)
Regional information
Cluster 1 2 1 0 (0) 2.23 Unknown: 2
Cluster 2 2 1 0 (0) 3.4 North: 1 – South: 1
Cluster 3 2 1 2 (100) 8.4 Unknown: 2
Cluster 4 2 1 2 (100) 15.0 Central: 2
Cluster 5 2 1 0 (0) 17.6 Unknown: 2
Cluster 6 2 0.98 2 (100) 22.8 Unknown: 2
Cluster 7 2 0.99 0 (0) 32.3 Unknown: 2
Cluster 8 2 0.97 0 (0) 32.8 Central: 1 – Unknown: 1
Cluster 9 2 0.92 0 (0) 33.1 Unknown: 2
Cluster 10 5 0.99 0 (0) 13.9 Unknown: 5
Cluster 11 6 1 0 (0) 12.6 Central: 1 – Unknown: 5
Cluster 12 7 1 0 (0) 7.8 Central: 6 – Unknown: 1
Cluster 13 34 0.98 3 (8.8) 35.4 North: 2 - Central: 21 -
South: 7 – Unknown: 4
In total, 13 highly supported clusters were identified (posterior root node support ≥0.90), with 2 to 34 Italian member taxa. Sampling region information was
unavailable for many taxa. For each cluster, the sample size, posterior root node support, presence of Q80K and the time spanned by the cluster, is listed. Clusters
are ordered according to sample size and time span
Fig. 3 a: A founder effect dominates the history of the Q80K clade. The branches in the HCV1a MCC tree are colored according to the inferred
amino acid at NS3 position 80 (see legend). All except five Q80K variants descend from a common ancestor that is inferred to have existed
around 1957 (95% HPD: 1947–1959). Posterior root node support is visualized in a selection of deeper nodes. Amino acids other than Q or K were
found in only 13 lineages. b: Histogram of the size of the (second) largest clade with an independent origin of Q80K among the plausible trees.
The size of the largest clade remains more or less constant, and the limited size of the second largest clade shows that most contemporaneous
Q80K lineages reside in the major Q80K clade. c: Histogram of the number of independent origins of a Q80K lineage in the plausible trees. This
shows that in the most plausible trees three to four de novo appearances of the Q80K variant appear
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gene using the dataset of [32]), showing that the latter
was an appropriate external calibration.
Discussion
In this work, we elucidated patterns in the HCV1a trans-
mission dynamics that are relevant for the Italian HCV
sequencing policy, with a focus on the NS3 variant
Q80K, which can affect success of simeprevir containing
drug regimens and serves as a model for other clinically
relevant RAVs. To this end, newly obtained Italian NS3
sequences were combined with all publicly available
sequences worldwide obtained from isolates with known
sampling time and location. Sequence evolution was
integrated with spatial diffusion at a country-level reso-
lution to assess the relative importance of local spread
versus virus importation into Italy. The within-Italy
migration dynamics were tentatively explored and the
opportunity was taken to concisely revisit the dating of
the highly successful Q80K founder event.
The clustering patterns of Italian strains with globally
sampled ones showed that HCV1a, including Q80K
strains, entered Italy on multiple occasions. The origin of
these lineages can be traced to both the US and Western
Europe, and no significant link with other locations was
found (Table 2). Few samples were available from other
regions with a considerable HCV1a burden, such as the
Andean Latin American and Caribbean regions (Table 1,
[38]). While this may have affected the inferred role of
the US as the origin (but see [8]), it does not affect our
findings that HCV1a, including Q80K strains, has been
introduced into Italy on multiple occasions.
The plot of the expected number of migration events
per year from the dominant origin locations (e.g. the
US and Western Europe) to Italy shows that in the
hypothetical situation of a 100% effective screening and
treatment of immigrants and short-term travelers of
these regions, approximately five to six lineages can be
prevented from initiating an ‘Italian’ transmission net-
work each year. Note that, because the sampling dens-
ity impacts the extent of clustering, this estimate is a
lower bound. Temporally resolving the seeding inten-
sity by origin region also revealed a switch in the rela-
tive importance between both locations, initially mainly
from the US, with European continental spread domin-
ating from the late 1960s, early 1970s onwards (Fig. 2a,
left panel).
Importantly, the Italian lineages are dispersed among
all clade 1 subclades and there are no clear differences
in migration pathways between clade I, which encom-
passes all but one of the Q80K strains, and clade II
(Fig. 1). This has several potential public health policy
implications. Because both virus import and local spread
shape the Italian HCV1a, and thus also the Italian Q80K
epidemic, immigrants and short-term travelers or other
(non-travelling) Italian citizens cannot be specifically tar-
geted or disregarded in a sequencing program. More-
over, since the origins of imported lineages in the Q80K
and other clades are shared, and the Italian epidemic is
usually seeded from those locations that contribute most
to the Q80K clade, also referred to as clade 1A [16], this
too cannot be used to distinguish populations in their
relative risk of failing with simeprevir.
The national patterns of virus movements were
explored by coarsely dividing Italy in a North, Central
and South region, not only because detailed geographical
data are only available for a subset of the Italian samples
(see Additional file 1: Table S1) but also because using a
higher-level resolution for this small dataset precludes
well-informed parameter estimations. Although it
remains difficult to extract general migration patterns
from a limited sampling, the extensive mixing of lineages
among different regions identified for both wild-type
and Q80K lineages shows that the Italian epidemic likely
is quite uniform and does not evolve in well-segregated
local sub-epidemics. Of note, because of this it is likely
that many unsampled Italian HCV1a lineages are part of
already detected Italian transmission networks and thus
represent the same introduction events (and origins) as
those of sampled lineages.
HCV is characterised by substantial amounts of among
lineage rate variation [32]. This cannot only interfere
with divergence time estimation [39, 40] but also with
phylogenetic inference [41, 42], and is to the best of our
knowledge for the first time explicitly modelled in our
timing of the Q80K origins. Moreover, unlike in earlier
work, the phylogeny and divergence times were co-
estimated using an integrated Bayesian approach that
appropriately takes the shared ancestry into account
and also avoids the risk of error propagation typical for
rate-smoothing procedures that rely on a pre-specified
topology. Our dating places the origin of the most suc-
cessful lineage in 1955 (95% HPD: 1947.3-1958.7). This
is far more recent than the penalised likelihood based
point estimate by McCloskey et al. [17] and demarcates
a more narrow interval than their linear regression
based estimate (1955, 95% CI: 1945–1963). This makes
that the earliest Q80K origin no longer overlaps with
the dates of World War II (WOII) and, in turn, renders
the hypothesis that the Q80K lineage was introduced
into Europe through large-scale movements of military
troops unlikely. Rather, this successful Q80K lineage
found itself at the right time at the right place to profit
from the post-WOII increase in parenteral iatrogenic
procedures and illicit drug use, both in the US and else-
where, including Italy [43, 44]. The majority of Italian
Q80K strains for which sampling region information
was available (156/183) were isolated in Central to
Southern and Insular areas, the regions from where
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most Italy-to-US emigrants originate [45]. As many of
these emigrants eventually returned - estimates range
from 11% to 73% for the first half of the 20th century
[46, 47] - the introduction of HCV1a via remigration is
an alternative hypothesis that deserves further explor-
ation. Other Western European countries, in particular
Germany and the UK, also have a history of intense
travel, migration and trade with the US, but large
discrepancies in the reported numbers of immigrants
arriving and leaving the US hamper a comparison of
the migration flow intensities (statistics US Homeland
Security). In this respect it is noteworthy that the
group of non-Italian European samples includes a rea-
sonable 67 German samples but only four UK isolates
(Table 1). The inclusion of additional data, in particu-
lar from the UK, can therefore be expected to ‘break’
some of the direct links between the US and Italy.
Additionally, Latin America and South-East Asia, for
which high HCV1a prevalence rates have been
reported [38], were underrepresented in our dataset.
This implies that a number of introductions into Western
Europe (or Italy) from these locations likely were not
detected. However, because Brockmann et al. [48] re-
ported less intensive migration links between Europe
and Latin America as compared to between Europe and
North America, and virus dispersal is usually linked to
the degree of human connectivity [49], we believe this
did not heavily impact our results.
The rate at which new virus genetic data is generated is
increasing as a result of upscaled sequencing efforts in the
context of DAA combination therapies. These are fre-
quently extensively annotated with socio-demographic and
clinical metadata, which can be used for a fine-grained
identification of processes that fuel an epidemic (see [50]
for a recent example for HCV). Unfortunately, such meta-
data are usually not deposited along with the virus genetic
data in public databases for reasons of privacy. Here, it has
been highlighted how scrutinizing the population level
transmission dynamics can still reveal information relevant
for intervention strategies provided basic annotations such
as sampling time and space are available.
Conclusions
In-depth phylogeographical analyses revealed that the
Italian HCV1a epidemic is shaped by complex patterns
of virus importation and sustained local and interre-
gional transmission. Because this precludes a clear
differentiation of Q80K presence/absence between sub-
populations, it may be cost-effective to test all HCV1a
patients eligible for therapy with simeprevir for the
absence of this polymorphism. Furthermore, this study
demonstrates the usefulness of a versatile analysis strat-
egy that can readily be applied in different regions or
countries, to other genetic regions in the HCV genome
such as the NS5A protein and to other measurably
evolving pathogens.
Additional files
Additional file 1: Table S1. The country-wide distribution of Italian
samples. Overall, 183 sequences were newly obtained from seven different
regions. The publicly available data trace back to the work by de Luca et al.
[14] (n = 67) and Paolluci et al. [51] (n = 30). The former samples have an
unknown distribution among the Lazio, Lombardy, Tuscany and Apulia
region. For the latter, it is only known that the patients visited the Fondazione
IRCCS Policlinico San Matteo, Pavia, Lombardy. (DOC 31 kb)
Additional file 2: Visualization. An interactive web-based visualization
of the phylogeographic history of HCV1a. Migration patterns of HCV1a in
general and in particular of the Q80K polymorphism are visualized in an
interactive web application, available at http://demo.luciad.com/rega/
?hepa&2d. A demo-movie with voice-over is accessible through a button
implemented in the application, explaining the possibilities of the tool. More
specifically, the world map is visualized in the upper panel, with the
countries sampled in this study highlighted in a color and labeled by their
name. The map shows how viral lineages are introduced/exported in/to
different countries throughout time, represented by jumping lines on the
upper panel. Viral lineages that circulate locally are represented by circles on
the world map, with their size proportional to the number of branches. The
visualization is simulated over time, using a fixed window of time as a filter.
The length of a jump on the map, is inversely proportionate to the length
of the branch in the phylogenetic tree. That is, longer geographic jumps on
the map indicate branches that quickly traveled over large distances, while
short jumps indicate branches that slowly traveled over relatively small
distances. The timing of these jumps is indicated in the lower panel, which
represents a timeline that plots new viral lineages over time. The colors in
this timeline match the region of the same color on the geographic map.
On the map, a darker color, indicates a larger viral lineage amount. Using
the tool, we can apply a color filter on the branches of the tree, visualizing
not only the phylogeographic history of HCV1a in general, but also of
variant Q80K. Migration jumps will be colored by amino acid polymorphisms
present at position 80 of the NS3 protein region, with amino acid Q indicated
in red, and variant K in yellow. All other polymorphisms (being not Q or K) are
colored blue, as indicated in the legend. (MP4 162 mb)
Additional file 3: Figure S1. The thirteen highly supported Italian
clusters indicated in the maximum clade credibility summary tree. The
highly supported Italian-only clusters are highlighted in green, and the
cluster number corresponding to the numbering in Table 3 is also
detailed. The red background marks the dominant Q80K clade. The
evolutionary distance bar at the bottom indicates the percentage of
nucleotide substitutions per site along each lineage. (PDF 50 kb)
Additional file 4: Table S2. Geographical distribution of Italian Q80K
lineages. For each Italian strain within the large Q80K clade, more detailed
regional information is listed. (DOC 29 kb)
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